ArticleCancer biology & therapy2023

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer.

Cha Len Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.